呼吸器診断とは、肺機能とそれに関連するプロセスを臨床的に検査することです。喘息、COPD、肺癌、気管支炎、肺線維症などを検出するための、機械的、放射線的、分子的な診断検査を含みます。肺活量測定、酸素濃度計、経皮的CO2モニタリング、鼻腔内吸気圧(SNIP)、胸部X線、コンピューター断層撮影(CT)スキャンなどの方法を使用します。睡眠検査は、場合によっては睡眠時無呼吸症候群や夜間低換気症候群の発生を特定・分析するために用いられます。呼吸器診断の世界市場は、拡大の余地が大きく、近い将来、新規企業の参入により競争が激化することが予想されます。競争に打ち勝つために、大手企業は製品の革新や技術開発に力を入れていくでしょう。
COPDをはじめとする肺癌などの重篤な呼吸器疾患は、喫煙者やアルコール摂取量の増加に加え、座りっぱなしの生活習慣やストレスの多い日常生活が原因で増加しています。さらに、COPD診断や外来治療のためのモノのインターネット(IoT)や人工知能(AI)の使用など、呼吸器診断検査のいくつかの技術的進歩が市場の拡大を後押ししています。呼吸器診断の市場は、さまざまな個人所有の病院や医療センターでの呼吸器診断装置の需要の増加、および政府と非政府機関(NGO)の両方が質の高い医療施設を誰もが利用できるようにする取り組みによっても推進されています。
市場を牽引しているのは、呼吸器診断システムの技術的進歩とイノベーションです。モニタリングシステムや電子吸入器などの最先端技術の活用が成長を後押ししています。さらに、先進国と発展途上国の両方で治療意識が高まっていることも、予測期間を通じて市場の成長に拍車をかけています。
目次
Contents
1. Executive Summary
2. Global Respiratory Diagnostics Market
2.1. Product Overview
2.2. Market Definition
2.3. Segmentation
2.4. Assumptions and Acronyms
3. Research Methodology
3.1. Research Objectives
3.2. Primary Research
3.3. Secondary Research
3.4. Forecast Model
3.5. Market Size Estimation
4. Average Pricing Analysis
5. Macro-Economic Indicators
6. Market Dynamics
6.1. Growth Drivers
6.2. Restraints
6.3. Opportunity
6.4. Trends
7. Correlation & Regression Analysis
7.1. Correlation Matrix
7.2. Regression Matrix
8. Recent Development, Policies & Regulatory Landscape
9. Risk Analysis
9.1. Demand Risk Analysis
9.2. Supply Risk Analysis
10. Global Respiratory Diagnostics Market Analysis
10.1. Porters Five Forces
10.1.1. Threat of New Entrants
10.1.2. Bargaining Power of Suppliers
10.1.3. Threat of Substitutes
10.1.4. Rivalry
10.2. PEST Analysis
10.2.1. Political
10.2.2. Economic
10.2.3. Social
10.2.4. Technological
11. Global Respiratory Diagnostics market
11.1. Market Size & forecast, 2020A-2030F
11.1.1. By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
11.1.2. By Volume (Million Units) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12. Global Respiratory Diagnostics Market: Market Segmentation
12.1. By Regions
12.1.1. North America:(U.S. and Canada), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.2. Europe: (Germany, UK, France, Italy, Spain, Russia and Rest of Europe), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.3. Asia-Pacific: (China, India, Japan, South Korea, Australia and Rest of Asia Pacific), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.4. Middle East and Africa: (Saudi Arabia, South Africa, UAE and rest of Middle East and Africa), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.5. Latin America (Brazil, Mexico and Argentina, Rest of South America), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2. By Product and Service Type: Market Share (2020-2030F)
12.2.1. Instruments and Services, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.2. Services and Software, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3. By Test Type: Market Share (2020-2030F)
12.3.1. Mechanical Tests, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.2. Obstructive Sleep Apnoea (OSA) Diagnostic Tests, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.3. Imaging Tests, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.4. Traditional Diagnostic Tests, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.5. Molecular Diagnostic Tests, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.6. Others, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4. By Disease: Market Share (2020-2030F)
12.4.1. Tuberculosis, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4.2. Asthma, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4.3. Chronic Obstructive Pulmonary Disease (COPD), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4.4. Lung Cancer, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4.5. Others, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.5. By End user: Market Share (2020-2030F)
12.5.1. Hospitals, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.5.2. Clinics, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.5.3. Reference and Clinical Laboratories, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.5.4. Others, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13. Company Profile
13.1. Philips Healthcare
13.1.1. Company Overview
13.1.2. Company Total Revenue (Financials)
13.1.3. Market Potential
13.1.4. Global Presence
13.1.5. Key Performance Indicators
13.1.6. SWOT Analysis
13.1.7. Product Launch
13.2. Abbott Laboratories
13.3. Biomerieux
13.4. Becton Dickinson
13.5. Thermo Fisher Scientific
13.6. Alere Inc.
13.7. Seegene Inc.
13.8. 3M
13.9. Bio-Rad Laboratories
13.10. SDI Diagnostics
13.11. COSMED
13.12. Masimo Corporation
13.13. Other Prominent Players
Consultant Recommendation
**The above-given segmentations and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.